Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 23, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 24, 2026.
Predicted vs. what happened
What happened
Reached its target in 59 days.
The thesis — published February 23, 2026
Arrowhead looks like a short-term rebound idea after a big drop. A Feb 11 note said there are over 100 early prescriptions for REDEMPLO, which could steady investor mood and shift attention to how the company executes sales. But a lower price target shows some analysts remain cautious. Trade with a small position and tight rules because the stock can move quickly.
Primary drivers
- Early REDEMPLO prescriptions support its sales story
- Drug pipeline could cause bigger moves if news is positive
- Biotech sentiment shifts fast and can lift the stock
- Analyst caution means wait for confirmation and use stops
How it played out
ARWR: target reached in 59 days
Lyra published ARWR on 2026-02-23 at $63.50 as a short-term rebound idea with 20% expected growth. The thesis pointed to early REDEMPLO prescriptions, possible pipeline news, fast shifts in biotech sentiment, and analyst caution that called for confirmation.
Inside the window from 2026-02-23 to 2026-05-24, the stock reached the $76.20 target in 59 days. It later peaked at $82 on 2026-05-14, a 29.1% gain. It ended at $74.95. The thesis played out. The target was reached, and the close stayed above the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.